Abstract P1-10-07: Efficacy and safety results from a randomized, phase II study of CC-486 in combination with fulvestrant in postmenopausal women with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) metastatic breast cancer (MBC)

Phase Ii Study ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Efficacy And Safety ◽

Randomized Phase Ii ◽

Abstract P5-11-01 : Phase 1 dose escalation study of a novel selective androgen receptor modulator (SARM), RAD140, in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-), metastatic breast cancer

10.1158/1538-7445.sabcs19-p5-11-01 ◽

2020 ◽

Author(s):

Erika Hamilton ◽

Patricia LoRusso ◽

Cynthia Ma ◽

Neelima Vidula ◽

Rebecca G Bagley ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Phase 1 ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Dose Escalation Study ◽

Receptor Modulator ◽

Abstract P5-11-02: Dose-escalation study of SAR439859, an oral selective estrogen receptor degrader, in postmenopausal women with estrogen receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer

10.1158/1538-7445.sabcs19-p5-11-02 ◽

2020 ◽

Author(s):

Mario Campone ◽

Aditya Bardia ◽

Gary A Ulaner ◽

Sarat Chandarlapaty ◽

Alice Gosselin ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Metastatic Breast Cancer ◽

Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Dose Escalation Study ◽

Efficacy and safety of palbociclib in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2

The Breast ◽

10.1016/j.breast.2021.07.017 ◽

2021 ◽

Author(s):

Karen Gelmon ◽

Janice M. Walshe ◽

Reshma Mahtani ◽

Anil A. Joy ◽

Meghan Karuturi ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Growth Factor Receptor ◽

Efficacy And Safety ◽

Post Hoc Analysis ◽

Epidermal Growth ◽

Post Hoc

Abstract PS10-14: Efficacy and safety of palbociclib (PAL) in patients (pts) with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) with preexisting conditions: A post hoc analysis of PALOMA-2

10.1158/1538-7445.sabcs20-ps10-14 ◽

2021 ◽

Author(s):

Karen Gelmon ◽

Janice M Walshe ◽

Reshma Mahtani ◽

Anil A Joy ◽

Meghan Karuturi ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Growth Factor Receptor ◽

Efficacy And Safety ◽

Post Hoc Analysis ◽

Epidermal Growth ◽

Post Hoc

116O Palbociclib (PAL) plus letrozole (L) as first-line (1L) therapy (tx) in postmenopausal Asian women with estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2-) metastatic breast cancer (mBC)

Annals of Oncology ◽

10.1093/annonc/mdw577 ◽

2016 ◽

Vol 27 (suppl_9) ◽

Cited By ~ 3

Author(s):

S-A. Im ◽

H. Mukai ◽

I.H. Park ◽

N. Masuda ◽

C. Shimizu ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Metastatic Breast Cancer ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Asian Women ◽

First Line ◽

Impact of prior treatment on palbociclib plus letrozole (P+L) efficacy and safety in patients (pts) with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2–) first-line advanced breast cancer (ABC): A PALOMA-2 subgroup analysis

Annals of Oncology ◽

10.1093/annonc/mdx365.011 ◽

2017 ◽

Vol 28 ◽

pp. v79-v80

Author(s):

R.S. Finn ◽

K.A. Gelmon ◽

J. Ettl ◽

J. Asselah ◽

A. Castrellon ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Efficacy And Safety ◽

First Line ◽

Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-016-3812-1 ◽

2016 ◽

Vol 157 (1) ◽

pp. 109-116 ◽

Cited By ~ 16

Author(s):

Daniel Rayson ◽

Sasha Lupichuk ◽

Kylea Potvin ◽

Susan Dent ◽

Tamara Shenkier ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Metastatic Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment

Current Medical Research and Opinion ◽

10.1185/03007995.2016.1157060 ◽

2016 ◽

Vol 32 (5) ◽

pp. 959-965 ◽

Cited By ~ 11

Author(s):

T. Bell ◽

J.P. Crown ◽

I. Lang ◽

H. Bhattacharyya ◽

G. Zanotti ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor Receptor ◽

Daily Activities ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor‑positive, human epidermal growth factor receptor 2‑positive breast cancer cells

Molecular Medicine Reports ◽

10.3892/mmr.2018.8580 ◽

2018 ◽

Cited By ~ 1

Author(s):

Seung Taek Lim ◽

Ye Won Jeon ◽

Hongki Gwak ◽

Se Young Kim ◽

Young Jin Suh

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Breast Cancer Cells ◽

Growth Factor Receptor ◽

Anticancer Effects ◽

Epidermal Growth ◽

Positive Breast Cancer

Abstract PD8-08: A phase 1/2 study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), as monotherapy and in combination with other anti-cancer therapies in postmenopausal women with ER-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC): AMEERA-1

10.1158/1538-7445.sabcs20-pd8-08 ◽

2021 ◽

Author(s):

Hannah M Linden ◽

Mario Campone ◽

Aditya Bardia ◽

Gary A Ulaner ◽

Alice Gosselin ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Phase 1 ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Cancer Therapies ◽

Anti Cancer ◽

Er Positive ◽